文献速递白血病

全反式维甲酸、三氧化二砷联合蒽环类药物诱导治疗急性早幼粒细胞白血病患者的疗效

[Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

该研究比较了三药诱导方案(全反式维甲酸+三氧化二砷+蒽环类药物)与双药诱导方案(全反式维甲酸+三氧化二砷)治疗急性早幼粒细胞白血病的疗效。结果显示三药诱导组在血液学缓解率、遗传学缓解率、分子学缓解率、诱导分化综合征发生率及远期复发率、总生存率、无病生存率方面均优于双药诱导组,且不良反应未见明显增加。

要点

  • 三药诱导组1个疗程血液学缓解率98.3%,双药诱导组87.3%,差异有统计学意义(P=0.017)。
  • 三药诱导组诱导分化综合征发生率0,双药诱导组12.7%,差异有统计学意义(P=0.005)。
  • 三药诱导组总生存率98.5%,双药诱导组86.5%,差异有统计学意义(P=0.018)。

核心结论

  • 在急性早幼粒细胞白血病的诱导治疗中,三药诱导方案(全反式维甲酸+三氧化二砷+蒽环类药物)的疗效优于双药诱导方案(全反式维甲酸+三氧化二砷)。

研究设计与样本

  • 2009年1月至2016年3月确诊并治疗的急性早幼粒细胞白血病患者184例,随机分为三药诱导组(58例)和双药诱导组(126例)。
  • 三药诱导方案为全反式维甲酸20 mg·m⁻²·d⁻¹第1~28天,三氧化二砷0.16 mg·kg⁻¹·d⁻¹第1~28天,去甲氧柔红霉素8 mg·m⁻²·d⁻¹或柔红霉素40 mg·m⁻²·d⁻¹第3~5天。
  • 双药诱导方案为全反式维甲酸联合三氧化二砷,剂量用法同上。
  • 184例患者中白细胞计数>10×10⁹/L者69例,白细胞计数≤10×10⁹/L者115例。

主要发现

  • 三药诱导组1个疗程的血液学缓解率、遗传学缓解率、分子学缓解率及诱导分化综合征发生率分别为98.3%、87.9%、72.4%和0,双药诱导组分别为87.3%、65.9%、51.6%和12.7%,差异均有统计学意义(P值分别为0.017、0.002、0.008、0.005)。
  • 在白细胞计数>10×10⁹/L的患者中,三药诱导组诱导分化综合征的发生率及早期病死率低于双药诱导组(0对15.6%,P=0.042;4.2%对15.6%,P=0.246)。
  • 在白细胞计数≤10×10⁹/L的患者中,三药诱导组诱导分化综合征的发生率也低于双药诱导组(0对12.3%,P=0.032),但缓解率及早期病死率两组差异无统计学意义(P值均>0.05)。
  • 三药诱导组的复发率、总生存率及无病生存率分别为0、98.5%、96.6%,双药诱导组分别为8.6%、86.5%、84.1%,差异均有统计学意义(P值分别为0.013、0.018、0.019);尤其是白细胞计数>10×10⁹/L的患者,三药诱导组优势更加明显。
  • 三药诱导组的胃肠道反应、肝功能损害、心肌损伤及头痛的发生率未见明显增加。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the efficacies of regimens of three-drug induction therapy (ATRA+ATO+anthracyclines) versus two-drug induction therapy (ATRA+ATO) in patients with acute promyelocytic leukemia (APL). Methods: Of 184 patients diagnosed with APL from January 2009 to March 2016, 58 patients underwent three-drug induction therapy, while the rest were treated with two-drug induction therapy. Three-drug induction therapy was of ATRA (20 mg·m(-2)·d(-1), d(1-28)) + ATO (0.16 mg·kg(-1)·d(-1), d(1-28)) + Idarubicin (8 mg·m(-2)·d(-1), d(3-5)) /daunorubicin (40 mg·m(-2)·d(-1), d(3-5)) , while two-drug induction therapy ATRA+ATO with the same doses and methods as above. Of 184 cases, 69 cases accompanied with WBC counts>10×10(9)/L, 115 cases with WBC counts≤10×10(9)/L at onset. Results: ①Short-term efficacy: After one cycle induction therapy, the rates of hematologic remission, genetic remission, molecular remission and induced differentiation syndrome (DS) in three-drug regimen group were 98.3%, 87.9%, 72.4% and 0 respectively, while those in two-drug regimen group were 87.3%, 65.9%, 51.6% and 12.7% respectively. In patients with WBC >10×10(9)/L, DS rate and early mortality in three-drug regimen group were lower than in two-drug regimen group (0 vs 15.6%, 4.2% vs 15.6%, respectively). In patients with WBC≤10×10(9)/L, DS rate in three-drug regimen group was also lower than in two-drug regimen group (0 vs 12.3%) , but there were no statistical differences in terms of relapse and early mortality. ② Long-term efficacy: The relapse rate, overall survival (OS) and disease free survival (DFS) in three-drug regimen group were 0, 98.5%, 96.6% respectively, while those in two-drug regimen group were 8.6%, 86.5% and 84.1% respectively; the advantages of three-drug over two-drug regimen, especially in cases of WBC >10×10(9)/L were observed. ③ Side effects: the incidences of gastrointestinal reaction, liver dysfunction, myocardial damage and headache in three-drug regimen group hardly increased. Conclusion: The efficacies of three-drug induction therapy were superior to two-drug one. 目的: 比较全反式维甲酸(ATRA)、三氧化二砷(ATO)联合蒽环类药物三药诱导方案与ATRA联合ATO双药诱导方案治疗急性早幼粒细胞白血病(APL)的疗效。 方法: 2009年1月至2016年3月确诊并治疗的APL患者184例,随机分为三药诱导组(58例)和双药诱导组(126例)。三药诱导方案为ATRA 20 mg·m(-2)·d(-1),第1~28天;ATO 0.16 mg·kg(-1)·d(-1),第1~28天;蒽环类药物去甲氧柔红霉素8 mg·m(-2)·d(-1)或柔红霉素40 mg·m(-2)·d(-1),第3~5天。双药诱导方案为ATRA联合ATO,剂量用法同上。184例患者中WBC>10×10(9)/L者69例,WBC≤10×10(9)/L者115例。 结果: ①近期疗效:三药诱导组1个疗程的血液学缓解率、遗传学缓解率、分子学缓解率及诱导分化综合征发生率分别为98.3%、87.9%、72.4%和0,双药诱导组分别为87.3%、65.9%、51.6%和12.7%,差异均有统计学意义(P值分别为0.017、0.002、0.008、0.005);在WBC>10×10(9)/L的患者中,三药诱导组诱导分化综合征的发生率及早期病死率低于双药诱导组(0对15.6%,P=0.042;4.2%对15.6%,P=0.246);在WBC≤10×10(9)/L的患者中,三药诱导组诱导分化综合征的发生率也低于双药诱导组(0对12.3%,P=0.032),但缓解率及早期病死率两组差异无统计学意义(P值均>0.05)。②远期疗效:三药诱导组的复发率、总生存率及无病生存率分别为0、98.5%、96.6%,双药诱导组分别为8.6%、86.5%、84.1%,差异均有统计学意义(P值分别为0.013、0.018、0.019);尤其是WBC>10×10(9)/L的患者,三药诱导组优势更加明显。③不良反应:三药诱导组的胃肠道反应、肝功能损害、心肌损伤及头痛的发生率未见明显增加。 结论: 在APL的诱导治疗中,三药诱导方案的疗效优于双药诱导方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ma RJ, Zhu ZM, Yuan XL, et al. [Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28655097. doi:10.3760/cma.j.issn.0253-2727.2017.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。